ATE537823T1 - Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin - Google Patents

Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin

Info

Publication number
ATE537823T1
ATE537823T1 AT05802853T AT05802853T ATE537823T1 AT E537823 T1 ATE537823 T1 AT E537823T1 AT 05802853 T AT05802853 T AT 05802853T AT 05802853 T AT05802853 T AT 05802853T AT E537823 T1 ATE537823 T1 AT E537823T1
Authority
AT
Austria
Prior art keywords
preeclampsia
resibufagenin
human beings
blood
patient
Prior art date
Application number
AT05802853T
Other languages
English (en)
Inventor
Jules B Puschett
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Application granted granted Critical
Publication of ATE537823T1 publication Critical patent/ATE537823T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT05802853T 2004-10-19 2005-09-23 Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin ATE537823T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61996904P 2004-10-19 2004-10-19
PCT/US2005/034075 WO2006044107A2 (en) 2004-10-19 2005-09-23 Method of treating human preeclampsia employing resibufagenin

Publications (1)

Publication Number Publication Date
ATE537823T1 true ATE537823T1 (de) 2012-01-15

Family

ID=36203374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05802853T ATE537823T1 (de) 2004-10-19 2005-09-23 Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin

Country Status (5)

Country Link
US (2) US7759329B2 (de)
EP (1) EP1804789B1 (de)
AT (1) ATE537823T1 (de)
CA (1) CA2584151A1 (de)
WO (1) WO2006044107A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858604B2 (en) * 2005-07-12 2010-12-28 Scott & White Healthcare Method of treating human volume expansion mediated hypertension employing resibufogenin
US20110008904A1 (en) * 2009-07-10 2011-01-13 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for determining if a patient has a traumatic brain injury and related apparatus
US20110207154A1 (en) * 2010-01-12 2011-08-25 Scott & White Healthcare Method for determination of marinobufagenin levels and compounds employable in such method
RU2472506C1 (ru) * 2011-11-07 2013-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Способ профилактики преэклампсии
US20180340947A1 (en) * 2017-05-23 2018-11-29 Jules B. Puschett Involvement of the bufodienolides in the diagnosis and treatment of post-traumatic stress disorder (ptsd)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6717599A (de) * 1966-12-30 1968-07-01
JPS5756500A (en) * 1980-09-22 1982-04-05 Otsuka Pharmaceut Co Ltd Novel bufadienolide-type steroid
US5770376A (en) 1992-12-02 1998-06-23 Biomedical Sciences Research Laboratories, Inc. Method of diagnosing and treating myocardial infarction and hypertension
US6306845B1 (en) * 1999-01-29 2001-10-23 The Trustees Of Columbia University In The City Of New York Method for treating demyelinating disease
AU2004210650C1 (en) * 2003-02-04 2010-01-14 The Administrators Of The Tulane Educational Fund Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus

Also Published As

Publication number Publication date
WO2006044107A3 (en) 2006-10-19
EP1804789B1 (de) 2011-12-21
EP1804789A4 (de) 2010-06-23
US8080539B2 (en) 2011-12-20
US20080261928A1 (en) 2008-10-23
WO2006044107A2 (en) 2006-04-27
US7759329B2 (en) 2010-07-20
CA2584151A1 (en) 2006-04-27
EP1804789A2 (de) 2007-07-11
US20100305079A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
DE60229406D1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
EA200801071A1 (ru) Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием
EP2298811B8 (de) Menschliche Anti-IFN-Gamma-neutralisierende Antikörper als selektive IFN-Gamma-Pfadhemmer
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
ATE493148T1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
DE60116256D1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
WO2007106893A3 (en) Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
EP1544214A4 (de) NICHT-NEUTRALISIERENDE ANTI-aPC-ANTIKÖRPER
EP1162457A3 (de) Vielfach-Koagulationstestsystem und Verfahren zu seiner Anwendung
WO2004071273A3 (en) Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus
ATE537823T1 (de) Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin
WO2005055956A3 (en) Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
JP2006517670A5 (de)
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
WO2007008855A3 (en) Method of treating human volume expansion mediated hypertension employing resibufogenin
DE3850728D1 (de) Methode zur Bestimmung des Verhaltens von Medikamenten in Lebewesen.
Shaw et al. Hyperbaric oxygen treatment induces platelet aggregation and protein release, without altering expression of activation molecules
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie
ATE484293T1 (de) Verfahren zur vorbeugung oder behandlung von diabetes